Treating asthma and COPD patients brings various benefits, such as better quality of life for patients and their families, higher output as a result of fewer days lost to sickness, and lower healthcare costs thanks to the improvement in patients’ health. Merely treating asthma patients with inflammation inhibitors yields social benefits of 127 million euros a year. This is the finding of research carried out by SEO Economic Research for De Long Alliantie Nederland.